報價延遲最少15分鐘:2026/09/04 01:51 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
83.205 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.07/1.01
|
|
企業價值
3.70B
|
| 資產負債 |
|
每股賬面淨值
7.90
|
| 現金流量 |
|
現金流量率
0.02
|
| 損益表 |
|
收益
182.95M
|
|
每股收益
0.28
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction. |
